project . 2021 - 2026 . On going

CancerAneuploidy

Understanding and targeting the functional consequences of aneuploidy in cancer
Open Access mandate for Publications European Commission
  • Funder: European CommissionProject code: 945674 Call for proposal: ERC-2020-STG
  • Funded under: H2020 | ERC | ERC-STG Overall Budget: 1,612,500 EURFunder Contribution: 1,612,500 EUR
  • Status: On going
  • Start Date
    01 Oct 2021
    End Date
    30 Sep 2026
  • Detailed project information (CORDIS)
  • Open Access mandate
    Research Data: No
Description
Aneuploidy, an imbalanced number of chromosomes or chromosome arms, is a distinct feature of cancer. Recent years have seen conceptual, methodological and technical advances in the field of cancer aneuploidy research, but we are just beginning to scratch the surface of the underlying biology, and the potential vulnerabilities of aneuploid cancer cells remain under-explored. Cancer aneuploidy is therefore a biological enigma and a missed opportunity for cancer therapy. Identifying the “Achilles heels” of aneuploidy remains a holy grail of cancer research. However, current models of aneuploidy fail to fully recapitulate the cellular consequences of aneuploidy in c...
Partners
Description
Aneuploidy, an imbalanced number of chromosomes or chromosome arms, is a distinct feature of cancer. Recent years have seen conceptual, methodological and technical advances in the field of cancer aneuploidy research, but we are just beginning to scratch the surface of the underlying biology, and the potential vulnerabilities of aneuploid cancer cells remain under-explored. Cancer aneuploidy is therefore a biological enigma and a missed opportunity for cancer therapy. Identifying the “Achilles heels” of aneuploidy remains a holy grail of cancer research. However, current models of aneuploidy fail to fully recapitulate the cellular consequences of aneuploidy in c...
Partners
Any information missing or wrong?Report an Issue